# Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

> **NCT06386302** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 184 (estimated)

## Conditions studied

- AML
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Venetoclax
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT06386302
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-05
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06386302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06386302, "Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06386302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*